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ABSTRACT 
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ii 
Obesity is a disease of major proportion in the United States. The Surgeon 
General has identified obesity as a national health problem that affects 
approximately 34 million Americans. 
The aim of this study was to investigate the very-low-calorie diet, Optifast 70. 
Measurements for resting energy expenditure (REE} and body composition via 
circumference measurements (CBF} and infrared photospectromerty (NIR} with a 
Futrex 5000 were collected at weeks 1, 7, 13, 19, and 25. Biochemical data, 
including serum chemistry panel (SMA-12} and complete blood count (CBC}, were 
collected on weeks 1, 5, 9, 13, 17, 21, and 25. Lipid profiles were drawn on weeks 
1 and 25. 
iii 
Particip~nts ranged in age from 27 to 64. Subjects' mean body mass loss 
was -20.4 kg ± 6.6 kg with a maximum body mass loss of -33.23 kg and minimum 
body mass loss of -9.770 kg. Mean loss in body fat mass using infrared 
photospectrometry as a measurement was -13.4 kg; mean loss of lean body mass 
was -4.2 kg. A significant change was noted in resting energy expenditure over the 
course of the diet, and a positive correlation was identified between loss of body 
mass and resting energy expenditure. No significant correlation was identified 
between the loss of lean body mass or body fat mass and its relationship to resting 
energy expenditure. Both circumference and infrared body fat measurements 
showed a positive correlation as the loss in body mass increased, making their 
reliability better as subjects approached desirable weight. In examining 
biochemical data, only cholesterol showed a significant change over the course of 
the diet; all other parameters remained within normal limits. Variations in patients' 
lipid profiles were identified, but no significant changes were noted. 
(101 pages) 
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INTRODUCTION 
Background of the Problem 
Obesity is a disease of major proportion in the United States. The U.S. 
Surgeon General has identified obesity as a national health problem, which affects 
millions of Americans, with an increase of as much as 30% in the last decade. 
Obesity is defined as greater than 120% of ideal body weight (1). Obesity is a 
multifactorial disease of which management is regularly unsatisfactory and 
frustrating, for both the clinician and patient. A body weight of greater than 120% 
of ideal has been associated with increased morbidity and mortality. Excess body 
weight has been recognized as a contributing factor to a wide range of chronic 
diseases such as diabetes, hypertension, coronary artery disease, and many 
orthopedic disabilities (2) . A 1992 National Institutes of Health (NIH) report 
reinforced the concept of improved outcomes for many of the chronic diseases 
associated with weight loss. Obesity, when left untreated, may have serious 
consequences. Untreated, the average obese woman may experience a 2% percent 
weight gain each year, which may gradually increase an already compromised 
health risk. Being significantly overweight is recognized as a chronic medical 
problem that may require long-term and even life-long treatment. The causes of 
obesity are many and complex and can include genetic, physiological, and 
biochemical factors that work together to form a complex disorder of energy 
metabolism. Today obesity still has no cure. Obesity is in itself a chronic disease 
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as stated by Stunkard (3). The misunderstanding of the nature of obesity has 
contributed to a stigmatization of obese persons and to inappropriate treatment 
programs that lack a multidisciplinary approach to weight loss. Various regimes 
have come about to treat the obese individual. These include behavioral therapy, 
exercise, drug therapy, surgery, and very-low-calorie diets. Each affects the 
treatment of obesity at differing levels (3). The very-low-calorie diet (VLCD) is one 
of these regimens. It has been administered throughout the United States and 
Europe and is essentially a modification of the fasting approach to weight loss. 
Safe and effective long-term weight loss programs are urgently needed in light of 
new data which conclude the prevalence of obesity is increasing in the United 
States, as much as 30% in the last decade (3). 
Abbreviations for specific words used throughout the text are listed in 
Appendix F. 
Purpose of the Study 
The purpose of this study was to evaluate the effects of a very-low-calorie 
diet program, specifically the Optifast-70 diet, on resting energy expenditure (REE), 
lean body mass (LBM), and fat body mass (FBM). Biochemical data including 
complete blood count (CBC), serum chemistry panel (SMA-12), and lipid profiles, 
on 17 outpatients. 
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Objectives 
1. Examine the· effects the Optifast-70 diet program has on weight loss and 
maintenance of weight loss through fasting, realimentation, and 6 weeks of 
maintenance. 
2. Examine the influence of the Optifast-70 diet program on resting energy 
expenditure during a period of fasting, realimentation, and maintenance. Determine 
if there is a significant correlation between resting energy expenditure and weight 
loss in association with any change in lean body mass and fat body mass before, 
during, and after a VLCD. 
3. Examine how the variation in intake and weight loss influences any 
change in respiratory quotients. 
4. Examine body composition(% body fat) via circumference measurements 
(upper arm, forearm, abdomen, hip, upper thigh, and calf). Determine the 
relationship of change in circumference and loss in body mass during the diet. 
5. Examine body composition, percent body fat, lean body mass, and fat 
body mass by near-infrared photospectrometry (NIR) during the course of the 
Optifast-70 diet. Determine the relationship of variation in body composition and 
loss in body mass. Determine if near-infrared photospectrometry is an accurate 
and reliable technique of assessing body composition in the obese population. 
Determine any correlation between this technique and the circumference technique 
in determining body composition. 
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6. Examine via descriptive analysis the effects of the Optifast-70 diet 
program on complete blood count (CBC) and serum chemistry panel (SMA-12) 
during fasting, realimentation, and maintenance of the Optifast-70 diet. 
7. Examine by descriptive analysis the effects the Optifast-70 diet has on 
lipid profiles, triglycerides, total cholesterol, high-density lipoproteins (HDL), low-
density lipoproteins (LDL), and very-low-density lipoproteins (VLDL) before the fast 
and after 6 weeks maintenance. Does the amount of body mass lost correlate to 
a change in lipid profiles, and does the ratio of HDULDL correlate with the amount 
of body mass lost? 
Limitations 
A limitation to this study was the small sample size of participants who 
completed the study (N=17). The second limitation was ending data collection at 
week 25. Continuing data collection after week 25 would have offered more insight 
into weight maintenance, fluctuation in resting energy expenditure, and other 
examined parameters. 
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LITERATURE REVIEW 
Very-Low-Calorie Diets 
The very-low-calorie diet (VLCD) has become a treatment for obesity. It is 
defined as any diet providing less than 800 calories per day (4). The history of the 
VLCD dates back to the early 1930's when patients were treated for 8 weeks with 
a 300-400 calorie diet with patients losing an average of 9.9 kilograms (5). Despite 
Frankie and Yang's great success, much of their work was forgotten until the 
1950's. In 1954 the Simeons diet was developed and used extensively by the 
medical profession. It consisted of approximately 575 kcal and was used for 6 
weeks with injections of human chorionic gonadotropin (6). Weight loss averaged 
between 9-14 Kg. After Simeons the next stage of treatment for obesity was the 
starvation diet. Bloom and his colleagues also promoted the starvation diet (7). 
The two major problems that lead to the abandonment of the starvation diet were 
physical danger to the patients, due to a loss of vital body protein stores, and poor 
maintenance of weight loss. By the mid-1970's, at least five deaths had been 
directly related to starvation. Two patients died of ventricular fibrillation. One patient 
with a history of hypertension and diabetes died of lactic acidosis. The last death 
resulted from a small bowel infarction (4). Recognizing that this loss of vital protein 
stores was undesirable, investigators in the late 1960's began using supplements 
of egg albumin as a protein source. A few years after this, Blackburn invented the 
term protein-sparing-modified-fast (PSMF). This terminology was later changed to 
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the (VLCD) (7). 
Currently there are two types of VLCD's. The protein sparing modified fast 
(PSMF) was developed by Blackburn and colleagues (8). This diet provides 1.5 
grams of protein per kilogram of ideal body weight. The protein is obtained from 
lean meat, fish, and fowl, consumed in three to four meals per day. No carbohydrate 
is permitted, and fat is limited to that present in protein foods. The other type of diet 
uses milk or egg based powdered protein formula consumed as a liquid three to 
four times per day. These commercially prepared diet products provide 30-70 
grams of protein, 30-45 grams of carbohydrate, approximately 2 grams of fat, and 
recommended levels of all vitamins and minerals (9). The relative merits of the two 
programs (VLCD, PSMF) have been debated. Proponents of the PSMF argue their 
diet teaches patients to handle conventional foods. This better eases the transition 
from the diet to controlled eating. Advocates of the liquid formulas contend their 
diet facilitates adherence by removing the temptation of conventional food. It has 
been concluded that patients vary considerably in their response to these two diets, 
so neither can be recommended categorically. 
The primary goal of a VLCD today is to lose body fat without jeopardizing the 
loss of lean tissue. During the early weeks of rigid dieting, approximately 3-6 grams 
of nitrogen are lost daily before establishing equilibrium. The loss of nitrogen during 
this period typically amounts to less than 4% of the total body nitrogen. Early 
researchers felt if this amount of nitrogen were replaced as protein, nitrogen 
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balance would be maintained. However, many of these studies were done 
immediately after a fast, and this increased the efficiency of protein use and the 
intensity at which nitrogen balance was retained (4). Blackburn et al. (8), and 
Bistrian et al. (10) recommended the use of 75 grams of protein for men and 55 
grams for women. These levels produced nitrogen balance in moderately obese 
adults within 2 to 3 weeks. Therefore, they perceived the optimal composition of 
the VLCD is to provide 1.5 grams protein per kilogram ideal body weight (IBW) per 
day. The protein must be of high biological value, and the diet should be 
supplemented with the recommended dietary allowances for all vitamins and 
minerals, especially potassium, magnesium, phosphate, sodium, and calcium. In 
studies conducted by Frankie and Yang (5}, nitrogen balance was maintained on 
as little as 31 grams and as much as 132 grams of protein daily within a period of 
14 to 21 days. Therefore, the actual amount of dietary protein required to achieve 
nitrogen balance during caloric restriction remains controversial, and these 
discrepancies illustrate the vast individual differences that may be observed in 
response to VLCDs. The existence of these differences underscores the need for 
careful medical supervision. 
The amount of carbohydrate used in the VLCD has caused much contention. 
Several researchers (6, 11) favored the use of carbohydrate (30-45 grams/day). 
Because of its protein-sparing effect, it prevents hyperuricemia and electrolyte loss 
due to diuresis, and it also decreases occurrence of orthostatic hypotension and 
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hunger. Researchers on the opposite end of the controversy (12,13,14) have 
proposed a notion of protein-sparing and fat mobilization that excludes dietary 
carbohydrate to maintain a high degree of ketosis and low levels of plasma insulin. 
These researchers believe ketones will replace glucose used by the brain and thus 
reduce gluconeogenesis. The low levels of plasma insulin will also increase the 
release of free fatty acids from adipose tissue and enhance fat mobilization. 
Furthermore, Blackburn et al. (13, 14) contended that the isocaloric substitution of 
carbohydrate for protein diminished the effectiveness of protein sparing therapy. 
Yang et al. (15) took another point of view concluding no significant difference in 
nitrogen loss after either diets of 132 grams protein per day or 66 grams of protein, 
and 59 grams of carbohydrate per day. Similarly, DeHaven et al. (16) showed no 
greater losses of nitrogen on a 3-week diet of 50 grams protein and 50 grams of 
carbohydrate than on a 1 00-gram protein diet. A carbohydrate intake of 30-40 
grams per day can decrease amino acid requirements by half. But the provision of 
80 grams or more of the carbohydrate per day can drastically reduce the amount 
of weight loss. The carbohydrate controversy continues. 
Vitamin and mineral supplementation with the use of a VLCD is essential if 
the diet is not already supplemented to the Recommended Dietary Allowances 
(RDA) for essential vitamin and minerals. Supplements need to include a 
multivitamin, 3-5 grams sodium chloride to replace the sodium Joss during diuresis 
and 3 grams (40 milliequivalents) of potassium to decrease ammonia genesis and 
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diminish nitrogen excretion by approximately 2 grams per 24 hours. Calcium 
supplementation is frequently prescribed at 400-800 milligrams per day. Fluids also 
play a major role, and it is recommended that patients drink a minimum of 1.5 to 2 
liters of fluid per day (17). 
Examples ofVLCDs currently in use include Optifast-70, currently known as 
Promed, Medifast, Health Management Resources, Medibase, and New Directions 
by Ross, along with several other over-the-counter liquid formulas such as Slimfast, 
Sweet Success, and others (9). In selecting patients for the VLCD, most 
investigators limit the diet to adults between the ages of 18-70, who are moderately 
obese (>115- 120% of ideal body weight [IBW]) or the morbidly obese (>200% of 
IBW). It appears, however, that patients over the age of 30 respond best to 
treatment. Patients are given a complete physical and psychological exam, 
including electrocardiogram, complete blood count, SMA-12, and complete 
urinalysis along with thyroid and lipid profiles. Contraindications for treatment 
include a recent myocardial infarction, cerebrovascular accident, active cancer, 
type I diabetes, hepatic disease, renal failure, depression, a deep vein thrombosis, 
and overt psychosis. Lithium therapy is now an exception, whereas it used to be 
a contraindication (4). Currently much emphasis is placed on cognitive and social 
support. 
During VLCDs, patients will sometimes be started on a balanced 1200 
calorie diet before beginning consumption of the formula. This may take place 2-4 
10 
weeks before beginning the diet (18). Once patients begin consumption of the 
formula, they consume their daily intake in five or greater feedings at regular 
intervals. Weight is dramatically reduced during the introduction of the liquid fast, 
averaging 2 to 5 kilograms in the first week. This initial weight loss is primarily due 
to diuresis, and afterward weight loss diminishes to average 1-2 kilograms per 
week for women, and 1.5-2.5 kilograms per week for men (4). 
It is vital that patients be seen weekly by a physician for a clinical exam 
including weight and blood pressure. Ketones, urinalysis, complete blood count, 
and SMA-12 are drawn every 4 weeks. 
Side effects of the VLCD may include postural hypotension, constipation, 
and cold intolerance. Other side effects such as dry skin, brittle nails, hair loss, and 
dizziness occur in less than 10% of all patients (19). One percent of patients 
complain of gall bladder symptoms. A study done by Kamrath et al. (20) concluded 
rapid weight loss associated with the use of a VLCD was associated with a 
significant incidence of gallstone formation. It is believed the weight losses 
experienced by VLCD reduce fatty changes in the liver, and may induce slight 
portal inflammation and fibrosis that may increase the incidence of gallstone 
formation (21 ). Another theory is that obese persons are at risk for cholesterol 
gallstones because their bile is saturated with cholesterol. Risk of gallstones is 
increased during the course of a VLCD because of increased bile cholesterol 
saturation index and gallbladder stasis. Gebbard et al. (22) found that gallstone 
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risk during a VLCD may be reduced by maintenance of gallbladder emptying with 
a small amount of dietary fat (10 grams per meal). Long-term complications may 
include the risk of ventricular arrhythmias. At times, large increases in a food intake 
or binging following severe caloric restriction can cause changes in metabolic rate 
and electrolyte imbalances that could result in cardiac arrhythmias. Seim et al. (23) 
concluded that a VLCD (800 kcal/d) for up to 3 months is not associated with 
significant electrocardiographic abnormalities or clinical cardiac complications, 
provided the patients have low cardiovascular risk at baseline of the diet. 
Inappropriate feeding during a course of time while following a severely restricted 
diet can also be associated with attacks of pancreatitis and cholecystitis (24). After 
the fasting phase of the diet that usually never lasts more than 3 months, the 
refeeding or realirnentation phase begins. This process takes place over 4-6 weeks 
and gradually reintroduces solid food (milk, vegetables, fruits, lean meat, fish, and 
fowl). Carbohydrate is reintroduced gradually to prevent an abrupt increase in fluid 
(25). This stage of the diet is ideal for the introduction of behavioral modification 
and controlled eating patterns because problem foods can be reintroduced 
cautiously (17). Followup care is essential for maintenance of weight loss. It 
includes further nutrition education, behavior modification, and exercise, with 
special emphasis on cognitive and social support. The VLCD appears safe and 
effective if four specific conditions are followed. 
1. The diet contains protein of high biological value. 
2. Duration of the diet is brief, 3 months or less. 
3. Use of the diet is restricted to patients 30% above ideal body weight, 
with no contraindicated physical conditions, ~ 50 pounds overweight. 
4. Patients receive frequent medical supervision. 
12 
The short-term effectiveness of the VLCD is dramatic, impressive, and 
directly associated with the duration of treatment. The mean rate of weight loss is 
1.5 to 2.5 kg per week for men and 1.0 to 2.0 kg per week for women (5). Weight 
loss associated with the VLCD is superior to other nonsurgical treatments. 
However, the long-term maintenance of weight loss after this type of dietary 
regimen is still a criticism. The American Dietetic Association (26) believes a major 
limitation of the VLCD is the poor long-term weight maintenance. They concluded 
with the current evidence that showed a higher percentage of dieters who complete 
a VLCD regain over half the weight they have lost. However, the inclusion of 
nutrition counseling , exercise, relaxation, and behavior modification offers hope to 
weight loss maintenance. Genuth et al. (27) showed with their research that at 22 
months, 56% of their subjects had regained more than half their weight. Hovell et 
al. (28) reported that maintenance at 1-2 years was apparent in only a small portion 
of patients completing treatment. They completed analysis of an 18-30 month 
weight loss maintenance program following treatment with both behavior 
modification and supplemented fasting procedures for 400 patients. Patients' who 
completed treatment lost a mean of 83.9% of their excess weight, but regained 
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between 59-82% of their initial weight by 30 months. Linder and Blackburn (29) 
reported the best results; they found that at 18-24 months follow-up, the original 
weight loss of 20.8 kilograms had decreased to only 14.5 kilograms. Kirshner et al. 
(30) examined data from 4,026 patients entering an Optifast program and found 
good results. Their results showed that at 18 months 58% of the men and 35% of 
the women who completed the treatment maintained their weight loss within 10 
pounds. 
Despite the diet regimen the American Medical Association Councils on 
Scientific Affairs have indicated a similar conclusion concerning very-low-calorie 
diets, that weight loss can be maintained following a controlled program of very-low 
caloric intake. In harmony with this belief, Wadden et al. (24) concluded that a 
comprehensive, long-term weight-control program is the only effective treatment for 
obesity. 
The Optifast Program 
The Optifast program came about during the late 1960's and early 1970's 
when Blackburn and coworkers developed the protein-sparing-modified fast. 
During this time Genuth and coworkers at the Mt. Sinai Medical Center were 
investigating the use of a protien sparing modified fast (PSMF) formula to reduce 
weight in obese patients (1 ). Genuth et al. (27) prescribed a combination of 45 
grams of calcium caseinate, 30 grams of glucose, a multivitamin tablet, and folic 
acid supplement to a group of 75 outpatients. This regimen was continued until a 
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reasonable weight loss goal was achieved. Success was defined as an average 
weight loss of 2 pounds per week with 60% (N=45) of the patients achieving 
successful weight loss. No severe clinical derangements occurred during the 
regime. Beneficial results included lowered blood pressure, improved glucose 
tolerance, and improvement in cardiac and pulmonary disabilities (31 ). 
From the research done by Genuth et al. (27) and the specific interests of 
Vertes, a hypertension specialist at Mt. Sinai Medical Center and member of this 
group, the Optifast program was developed. Since Genuth's original formula was 
unpalatable, Vertes and Genuth turned to the Delmark Company (formerly Sandoz 
Nutrition and now Novartis Nutrition Corporation) to manufacture a more palatable 
Optifast formula (18) . Today there is only one Optifast formula in use, Optifast-800. 
The Optifast-70 formula was phased out of the program, and the only 
formula available is the Optifast-800 formula. Novartis Nutrition Corporation 
rationale for one formula was: 
1. The difference in weight loss between the two formulas is negligible. 
2. The BOO-calorie products are richer in taste. 
3. The government is imposing stricter regulations on weight management 
and the company wishes -to be proactive. 
The original Optifast-70, used in this study, contained 70 grams of protein, 
30 grams of carbohydrate, and 2 grams of fat and provided 420 calories per day. 
Past nitrogen balance studies have concluded this formula adequately spared body 
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protein while inducing rapid weight loss. Vitamins and minerals are supplemented 
adequately to meet the recommended dietary allowance, and the 2 grams of fat 
maintained appropriate levels of serum fatty acids. The 30 grams of carbohydrate 
the formula contained helped conserve lean body mass and maintained electrolyte 
balance (1 ). 
The Optifast-800 formula currently provides 800 calories daily, 70 grams 
protein, 100 grams of carbohydrate, and 13 grams of fat along with vitamins and 
minerals to meet the recommended dietary allowance. At the time of this study the 
energy content of this formula was for individuals who had less than 50 pounds to 
lose or who for medical reasons did not qualify for the Optifast-70 formula ( 1 ). 
However, as stated earlier, the program has now changed, and studies have shown 
no significant difference in weight loss between the two formulas. 
The Optifast program was developed for the treatment of individuals with 
medically significant obesity who by means of weight loss may experience 
improvement in obesity-related health problems (1 ). The fasting regimen consists 
of a 12-week period during which patients ingest only the Optifast formula and 
noncaloric beverages. The realimentation phase follows the fasting phase. During 
this time solid food is gradually reintroduced, and patients slowly progress to a solid 
diet. Rigid guidelines have been developed for acceptance into the Optifast 
program. To qualify, persons must be at least 130% of ideal body weight or 50 
pounds overweight. Patients must have no history of a myocardial infarction, 
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cerebrovascular accident, diabetes with ketoacidosis, chronic steroid use, bleeding 
ulcers, active thrombophlebitis, or psychiatric problems. After the patients have 
undergone a complete physical exam, ECG, and thorough laboratory tests, they are 
admitted to the program (1). 
Patients are under constant medical supervision during the entire diet, and 
the physician treats any medical problems that occur while the dietitian and 
behavioralist monitor diet compliance. 
The Optifast program consists of several components that provide the 
education and support patients require for successful weight loss and maintenance 
with special emphasis on expanded behavioral modification and more focus on 
cognitive issues. The multidisciplinary approach taken provides patient education 
related to nutrition, behavior modification, and exercise. This teaches patients how 
to examine previous lifestyle behaviors, and to detect the problem or problems that 
may have contributed to their obesity. 
Optifast centers in the U.S. are established based on regional population, 
usually to support at least 150 patients. In 1987, there were approximately 400 
hospital-affiliated, clinic-based programs established including approximately 15 
university hospital programs. More than 200,000 obese individuals have received 
medically supervised treatment through Optifast with 80% of those individuals 
losing 40 pounds or more (1). In a study conducted by Kanders et al. (32) they 
examined weight loss and health benefits associated with the Optifast program in 
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the treatment of obesity. Their conclusions support the notion that a 10-20% weight 
loss may be the appropriate treatment goal for a single weight loss intervention as 
it may improve obesity-related problems. 
Participants in the Optifast programs consisted of approximately 70% women 
who range in age from 25 to 50 years of age (1). As stated earlier, participants over 
the age of 30 seem to have the best results. In 1992, Sandoz Nutrition, now 
Novartis Nutrition, changed the program title to Premed secondary to the bad 
publicity involved with the Optifast name. 
Resting Energy Expenditure 
During the last decade there have been many studies conducted examining 
the effects of dieting on resting energy expenditure (REE). People on restricted 
diets often show a considerable decline in REE (33, 34, 36). It was stated that if 
energy expenditure were reduced, it could become more difficult for the reduced 
obese individual to achieve further weight loss, or to maintain a reduced weight. 
There is much controversy about whether any body parameter can effectively 
explain REE (34). Bray et al. (31) concluded that oxygen consumption of obese 
patients is better correlated with fat tissue than with lean tissue. This means a 
reduction in fat must inevitably cause a reduction in energy expenditure and so 
make further weight loss difficult to achieve or sustain. If, however, lean tissue 
determines energy expenditure, the current diets that seek to spare lean tissue and 
preserve energy expenditures appear appropriate. Barrows and Snook (34) 
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investigated the long-term effects of a VLCD, specifically Optifast-70, on resting 
energy expenditure. They conducted three resting metabolic readings, before the 
fast, after the fast, and after 5 weeks of realimentation. They concluded that a 
significant drop in REE occurred during the diet, and REE remained lower following 
refeeding. They did not examine REE during the fast to see when the initial decline 
began nor did they examine REE during the maintenance period to see if REE 
returned to prediet levels. 
In a study conducted by Coxon et al. (37), a comparison was made between 
fat free mass (FFM) and the change in REE between two groups of dieting female 
subjects. They found the greater the weight loss the greater the decrease in REE. 
The ratio of REE/FFM remained the same, and no evidence suggested the rate of 
weight loss was associated with any detriment to body composition or metabolic 
rates. Wadden et al. (4) conducted a study on the long-term changes in metabolic 
rates associated with consumption of a VLCD. He examined the short-term and 
long-term changes in resting energy expenditure associated with the consumption 
of a VLCD, Optifast -70, and a 1000-1200 kcal balanced deficit diet. He concluded 
a reduction in REE associated with the consumption of a VLCD could be limited to 
the actual period that the diet was consumed . The REE increased rapidly, to 
approximately 98% of the baseline, when the patients stopped consuming Optifast-
70 and returned to a 1000-1200 kcal balanced diet. 
However, other studies examining long-term energy intakes on resting 
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metabolisms have been conducted using other VLCD plans. Welle et al. (38) 
concluded that a decrease in REE of 9.4% was shown in their investigations after 
5 weeks of a diet (472 kcalld). The lowest values of REE they measured, however, 
were similar to REE values of lean to moderately obese women. Nevertheless, 
these values were not significantly lower than predicted values. Rattan et al. (39) 
examined REE at four intervals: 1) before the diet, 2) after 2 weeks of a VLCD, 3) 
at the end of 8 weeks of a VLCD, and 4) at the end of 8 weeks of maintenance. 
They observed that the metabolic rate decreased to 86% of the original value by the 
end of the 8 weeks of the diet. Resting energy expenditure then recovered to 93% 
of predicted values by the end of 8 weeks of maintenance on a 1500 kcal diet. No 
losses in REE were noted beyond that expected from the loss of fat mass itself. 
Elliot et al. (40) assessed the potential long-term effects of weight loss on REE and 
body composition in obese women. Resting energy expenditure was measured via 
indirect calorimetry before weight loss, during the protein sparing modified fast, and 
for 2 months while at a stable reduced weight. Resting energy expenditure 
decreased significantly with the initiation of the fast. No significance was noted 
between resting energy expenditure levels during the fast and at a stable reduced 
weight, but values were significantly less than predicted. The decrease in REE was 
not contributed to the decrease in lean body mass but paralleled the loss of fat body 
mass. Franssila-Kallanki et al. (41) reached a similar conclusion in their study that 
a decrease in basal energy expenditure by 10.7% with weight loss was associated 
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with a loss in fat mass rather than with loss of lean body mass. 
Valtuena et al. (42) examined the respiratory quotient as a prognostic factor 
in weight-loss rebound. They concluded after a 28-day rapid VJeight loss diet that 
if the patients' respiratory quotients were in the lower range (<0.72), their more apt 
to maintain their weight loss. Patients in the higher respiratory quotient range 
(>0.75) were less able to maintain weight loss in the follow-up period. They 
concluded an appropriately measured respiratory quotient may be a useful indicator 
of the effectiveness of VLCD used to induce rapid weight loss (42). 
There are various key factors in weight loss and gain that include age, fat 
mass, lean body mass, sex, and thyroid hormones. Therefore, the persistence of 
altered metabolism, which occurs with a VLCD, and the influence of refeeding and 
long-term, low energy intakes continue to be extensively studied. There continues 
to be a need to conduct further in-depth examinations of the effects of dieting on 
resting energy expenditure. 
Anthropometries 
With the increasing use of the VLCD, there is a need to examine further the 
variations in body composition and pattern of weight loss that often accompany 
such radical treatments for obesity (43). Franssila-Kallanki et al. (41) identified in 
their study a decrease in body weight from 105.3 .:t 4.6 Kg to 94.1 .:t 4.0 Kg. This 
weight reduction was determined to be primarily a reduction in fat mass from 47.2 
3.6 Kg to 37.7 .± 3.0 Kg. Lean body mass decreased only slightly from 58.0 .:t 2.0 
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to 56.4 ± 1.8 Kg. Researchers have suggested that anthropometric measures may 
be inadequate for the clinical assessment of body composition in obese patients 
(43). Barrows and Snook (35) examined the effects of high protein, VLCD on 
anthropometric parameters of obese women. They used the Optifast-70 diet 
specifically, and tested the validity of nine previously published equations for 
predicting the body fat of obese women before and after weight loss. In addition, 
various anthropometric parameters (circumference and skinfolds) were used to 
develop multiple regression equations that would better predict the body 
composition of patients before and after weight loss. They concluded that body 
weight and circumference measurements were the variables most strongly 
associated with body composition before weight loss. After weight loss, only those 
circumference measures in the body trunk region (abdomen, maximum abdomen, 
and buttocks) remained significantly correlated with body composition. Katch and 
Katch (44) also contended these circumferences should be the preferred method 
to predict percent body fat when a one-time, accurate assessment is needed. 
Equations are available for both men and women. 
Near-infrared photospectrometry (NIR), based on the principle of light 
interaction with organic material , has been used for assessing body composition(% 
lean body mass, % fat mass, and % body water). Kamrath et al. (20) used infrared 
photospectrometry to assess body composition in 11 moderately obese patients 
treated for 8 weeks with a diet providing 605 calories. They found no excess loss 
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of fat free mass. Davis et al. (45) evaluated the infrared technique in 85 subjects, 
differing in age, gender, skin color, and body composition. They were evaluated 
with the following results: a test-retest reliability of 94% based on intraclass 
correlation. The mean of the measures yielded a reliability coefficient of 98%. This 
preliminary analysis suggests that body composition can be assessed with excellent 
reliability and good validity (46). Dotson (47) estimated the body composition in 
children by near-infrared photo spectrometry. A heterogeneous group of students 
(320 males and 272 females) from 5 to 13 years old was randomly sampled . Data 
were collected for age, height, waist and neck circumferences, weight, skinfold 
measurements, and NIR. Coxon et al. (37) used both bioelectrical impedance and 
infrared (Futrex-5000) to study body composition in 26 patients on a VLCD. They 
found both techniques correlated very well (r = 0.95-0.99) on weekly analysis. 
These methods were validated with a subset of 16 patients who were measured 
with hydrodensitometry and by the skinfold technique. The correlation among all 
techniques was quite satisfactory. Brodie et al. (48) examined body fat estimation 
methods. They compared hydrodensitometry, bioelectrical impedance, BC-3000 
analyzer, infrared (Futrex-5000), and skinfold measurements. There was a 
nonsignificant difference between the means. The infrared technique had a 
standard of error of the mean approximately half the values of the others. Infrared 
was also found to have a low operator error, was quick and reliable, but expensive. 
Conway et al (49) estimated body composition in 53 adults by infrared and 
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compared results from deuterium oxide dilution (r = 0.94), skinfold (r = 0.90), and 
ultrasound (r = 0.89) measurements. They concluded infrared was a safe, 
noninvasive, rapid, easy to use method, and could prove successful in predicting 
percent body fat, specifically in the obese. This is a relatively new technique and 
research is limited, especially in the obese population. Through infrared 
photospectrometry and body circumference measurements the effects of Optifast-
70 diet on body composition will be examined to see if a correlation exists between 
the two techniques. A determination of the accuracy of infrared photospectrometry 
in measuring body composition of obese women will also be examined. 
Biochemical 
It is crucial that the VLCD be supplemented with vitamins and minerals to 
meet the Recommended Dietary Allowances. A diminished dietary intake can 
induce major changes in electrolyte balance. Weight loss on a VLCD is initially 
greater than can be accounted for from endogenous and exogenous protein and fat 
metabolisms secondary to diuresis (50). Sodium loss exceeds that produced by 
dietary sodium. Sodium is the major extracellular cation, and the reduction in 
extracellular fluid volume that occurs via diuresis may result in decreased blood 
volume, and decreased serum sodium. It has been reported the major side effect 
experienced by patients on a very-low-calorie-diet is mild posturallightheadedness 
occurring within the first 2 weeks, perhaps related to diuresis and a loss of sodium. 
Adequate potassium is necessary to achieve optimal protein-sparing therapy during 
• 
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a VLCD. The protein sparing characteristics of the VLCD can increase potassium 
requirements (9). Sapir et al. (50) reported nitrogen wasting caused by losses of 
urinary ammonia during starvation could be eliminated by adequate potassium 
supplementation and urinary alkalinization, thus supporting the conclusion that 
potassium is necessary for optimal protein sparing-therapy. Recommendations for 
potassium intakes are between 2 and 3 grams per day. Calcium ions have many 
physiological functions besides being a principal component of skeletal tissue. It 
plays a vital role in a variety of essential physiologic and biochemical processes 
such as blood coagulation, neuromuscular excitability, transmission of nerve . 
impulses and activation of enzyme reactions, and hormone secretion (50). Because 
of the major importance of calcium in the diet it is essential that the liquid VLCD 
contain the Recommended Dietary Allowance. In addition, an extra 400 to 800 
milligrams of calcium per day should be provided. The phosphate ion is essential 
for the metabolism of carbohydrate, lipids, and protein. It functions as a cofactor for 
a multitude of enzyme systems and contributes to metabolic potential as a high-
energy phosphate compound (50). The average daily requirement for phosphorous 
is between .8 and 1.2 milligrams per day. A source for dietary phosphorous in the 
American diet is in nonnutritious soft drinks. The individuals on a liquid VLCD are 
allowed to consume noncaloric beverages such as soft drinks. Therefore, 
phosphorous requirements may not be important. 
Data are limited on the effects of the VLCD on serum electrolytes. Volioritch 
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et al. (52) examined biochemical data of patients involved in a clinical trial VLCD 
(Cambridge diet of 330 kcal/day). No change was seen in hematocrit, hemoglobin, 
or serum electrolytes [sodium (Na), potassium (K), chloride (CI), calcium (Ca), 
phosphorous (P), magnesium (Mg), zinc (Zn)]. Significant changes occurred within 
the normal ranges of globulin, C:reatinine, uric acid, albumin, cholesterol, 
triglycerides, and iron. Kreitzman et al. (51) concluded the initial shift in lab values 
may reflect homeostatic adjustments to a new dietary regimen, and the one medical 
concern is the elevation of serum uric acids that may predispose a patient to gout. 
Commercially prepared liquid formula diets (such as Optifast-70) may contain some 
or all of the major electrolyte supplements. Descriptive analysis of serum electrolyte 
levels during the very-low-calorie regimen, realimentation, and maintenance will 
provide a more thorough understanding of the metabolic effects VLCDs have on 
electrolyte balance. 
Elevated plasma cholesterol (values >220 mg/dL) according to American 
Heart Association guidelines have been associated with an increased risk of 
coronary heart disease. Cholesterol levels can be responsive to changes in body 
weight, diet, and exercise. It has been concluded that weight loss can have a 
significant impact on serum lipid levels, including triglycerides, total cholesterol , 
high-density lipoprotein (HDL), and low-density lipoprotein (LDL). 
Several studies have confirmed that plasma lipid values decrease during a 
VLCD, with serum triglycerides falling significantly in both men and women after 
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weight loss (53). In an investigative study conducted by Inoue et al. (54), 
reductions in body weight from 87.3 .± 3.8 Kg to 76.4 .± 2.8 Kg in 4 weeks 
significantly decreased fasting blood glucose, serum triglycerides, and serum total 
cholesterol levels during a VLCD. Weight loss was associated with decreases in 
fasting glucose from 110.4 .± 7.1 mg/dL to 80.8 .± 2.0 mg/dL, tryglycerides from 
150.1 .± 8.3 mg/dL to 107.2 .± 4.3 mg/dL and cholesterol from 204.6 .± 6.5 mg/dL to 
157.1 .± 6.0 mg/dL, respectively, in 4 weeks. Studies evaluating the influence of 
weight loss on high-density lipoprotein, cholesterol, and other lipoproteins are 
somewhat limited. The studies conducted yielded conflicting results. Weight loss 
has been reported to increase high-density lipoprotein cholesterol levels, decrease 
low-density lipoprotein cholesterol levels, or produce no change (55). 
Kreitzman et al. (51) showed conclusive evidence of decreased serum 
cholesterol and triglyceride levels after weight loss on a VLCD with serum 
electrolytes and serum protein levels remaining stable. Wadden et al. (4) saw a 
significant decrease in total serum cholesterol in 20-25% of patients on a VLCD. 
The largest reduction was seen in low-density lipoprotein (29% decrease); some 
decrease was also noted in high-density lipoprotein (28% decrease). Typically, 
women have a decrease in high-density lipoproteins following a VLCD, but men 
have an increase in high-density lipoprotein. Brownell and Stunkard (56) concluded 
women show a significant decrease of 3.3% in high-density lipoprotein levels after 
weight loss, with a 4. 7% decrease in levels. Parenti et al. (57) analyzed total 
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cholesterol, high and low-density lipoproteins, and triglycerides every week for 8 
weeks of a VLCD. They concluded all values decreased. However, low-density 
lipoprotein fell, then returned to normal at the end of the program. Consequently, 
the HDL-LDL ratio did not change. Gebbard et al. (22) concluded weight loss 
reduced bile cholesterol saturation and improved high-density lipoprotein (HDL) 
levels. Because of the variable influences weight loss has on serum lipids along 
with the few prospective studies of the effects of weight loss changes in plasma lipid 
levels, evaluating the specific effects the Optifast-70 diet on plasma lipids is 
important. 
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METHODOLOGY 
Restatement of Purpose 
The purpose of this study was to evaluate the effects of a very-low-calorie 
diet program, specifically Optifast-70, on resting energy expenditure, body 
composition including percent body fat, lean body mass (LBM), and fat body mass 
(FBM), using body circumference measurements and near-infrared photo 
spectrometry. Also examined were the effects the diet program had on biochemical 
data, including complete blood count (CBC), serum chemistry panel (SMA-12), and 
lipid profile, on 17 outpatients during an Optifast-70 diet treatment program. 
Subjects and Recruitment 
Subjects for this study had participated in the McKay-Dee Hospital Optifast 
Program, Ogden, Utah. They included 25 volunteers from the outpatient population 
attending the Optifast Diet Program. The participant letter and consent form are 
noted in Appendix B, and Appendix C. The study was approved by the Utah State 
University Review Committee on Human Research and by the Institutional and 
Medical Review Board at McKay-Dee Hospital. The review board letter is shown 
in Appendix A 
Procedures 
Before being accepted into the diet study, all subjects were given a 
preliminary physical and psychological screening. Primary subject selection criteria 
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were as follows: 
1. Females aged 20-70 years 
2. A typically sedentary lifestyle 
3. A normal electrocardiogram (EKG) 
After successfully completing the initial health screening process, each 
subject was seen on an appointment basis for the initial measurement of resting 
energy expenditure, body circumference measurements, and near-infrared photo 
spectrometry. Measurements for each of these parameters were collected: 
1. Before the fast (week 1) 
2. During the fast (week 7) 
3. After the fast (week 13) 
4. After realimentation (week 19) 
5. After six weeks of maintenance (week 25). 
Biochemical data including a serum chemistry panel (SMA-12) and complete 
blood count (CBC) were collected before the fast, and on weeks 5, 9, 13, 17, 21, 
and 25. Normal laboratory values for the serum chemistry panel and complete 
blood count are noted in Appendix G. 
Fasting lipid profiles were drawn before the fast (week 1) and after 6 weeks 
of maintenance (week 25). 
Each participant's height was taken to the nearest 0. 1 centimeters before the 
fast, and weights were taken weekly to the nearest 0.001 kilograms (Kg). 
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Body composition was determined by using circumference measurements 
and following standard procedure (46). Measurements were taken to the nearest 
0.1centimeter with a cloth measuring tape pulled tautly but not tight against the skin 
at designated points on the right side of the body: 
1. Bicep - the midpoint between the shoulder and the elbow with the arm 
straight, palm up and extended in front of the body. 
2. Forearm- widest point between the wrist and elbow. 
3. Abdomen - one inch above the umbilicus 
4. Upper thigh -just below the buttocks 
5. Calf- widest point midway between the calf and ankle. 
Body composition of each patient was determined by near-infrared 
photospectrometry using a Futrex-5000 fitness computer. Two measurements were 
taken from the prominent arm, midway between the shoulder and the elbow (bicep), 
and these were averaged. 
Resting energy expenditure was determined by indirect calorimetry with a 
Beckman Metabolic Cart through the Respiratory Therapy Department at McKay-
Dee Hospital. Actual resting energy expenditure (AREE) was calculated from 
oxygen consumption (V02) and carbon dioxide production (VC02). Predicted 
energy expenditure (PREE) was calculated using the Harris-Benedict equation for 
women (655 + (9.6) x (WT (Kg)) + (1.7 x HT (em)) + (4.7 x Age). A respiratory 
quotient (RQ) was determined following the required standardized conditions for 
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subject preparation and data analysis. Subjects were post-absorptive before 
testing, and each subject was encouraged to have the measurement taken at the 
same time of day during each week the data were collected to decrease variability. 
Measurements were made in a quiet thermoneutral environment with patients 
resting in a supine position. Subjects had no voluntary muscle activity during the 
measurement. All data used to derive resting energy expenditure were taken 
during a "steady state." 
After the initial measurement was collected at week 1, all subjects began 
consuming the liquid fasting supplement, Optifast-70. Water, noncaloric 
beverages, and 25 optional calories were allowed besides the Optifast-70 formula. 
During the study the subjects were required to attend the clinic weekly to 
obtain weight, blood pressure, and pulse measurements and to insure dietary 
compliance. All subjects remained on the diet until they attained their desired goal 
weight, completed the fasting phase, or noncompliance was evident. After 
realimentation the maintenance period began. During this 6-week period of time 
each subject was gradually reintroduced to solid food. This entailed behavior 
modification, and identifying eating patterns necessary for maintenance of weight 
loss. 
Statistical Analysis 
Analyses of variance (ANOVA) were completed for each parameter 
investigated using time as the dependent variable. By-variant plots and frequency 
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data tables were completed on all data examined in the study. Stepwise regression 
was completed to identify how the change in weight related to all variables being 
examined in the study over time. 
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RESULTS 
Body Mass 
Mean body mass lost during the VLCD program was -20.44 Kg :t 6.62 Kg 
with a maximum loss of -33.23 Kg and a minimum loss of -9.77 Kg. Multivariate and 
univariate tests of significance reflected a significant (p < .001) change in body 
mass over time both between subjects and within subjects. Table 1 reflects the 
mean body mass of subjects before, during, and after the fast, 6 weeks into 
realimentation and 6 weeks into maintenance. Figure 1 represents a descriptive 
picture of the mean change in body mass of subjects over time. 
TABLE 1. 
The mean body mass (Kg) of subjects over the course of the diet program. 
Variable 
Week Body Mass (Kg) so N 95%CI 
1 100.96 13.770 17 93.637-100.313 
7 89.23 12.374 17 82.641-95.828 
13 83.09 13.262 17 76.022- 90.156 
19 79.61 11.772 17 73.334- 85.880 
25 80.53 11.527 16 74.391-86.675 
(p<.001) 
Resting Energy Expenditure 
MAN OVA measurements for the analysis of variance were completed on 
5 points of actual resting energy expenditure (AREE) and predicted resting energy 
expenditure (PREE) over time (weeks 1, 7, 13, 19, 25). Multivariate and univariate 
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FIG. 1. The change in body mass in (Kg) over the course of the diet program. 
TABLE 2. 
The actual resting energy expenditure of subjects over the course of the diet. 
Variable 
Week Mean (Kcal) so N 95%CI 
1 1657 212 17 1543-1770 
7 1503 203 17 1394-1611 
13 1441 207 17 1330-1551 
19 1429 167 17 1340-1519 
25 1500 211 16 1387-1613 
(p<.001) 
35 
tests of significance (s = 1, m = 1, n = 5) both reflected significant changes (p < 
.001) in actual and (p < .001) predicted resting energy expenditure over the course 
of the diet program, as identified in Tables 2 and 3. However, when examining the 
mean difference between actual and predicted resting energy expenditure no 
significant change (p < .409) was noted over the course of the diet. Table 4 
identifies the relationship between the difference in means for actual and predicted 
resting energy expenditure over the course of the diet. When comparing the mean 
values of actual resting energy expenditure and predicted energy expenditure per 
subject, using univariate and multivariate tests, a significant change (p < .002) was 
noted in actual and predicted resting energy expenditure over the course of the 
diet. Figure 2 outlines the relationship between actual and predicted resting energy 
expenditure over the course of the diet. Table 5 identifies the positive ·correlation 
between the amount of body mass lost and actual resting energy expenditure over 
the course of the diet. When examining the relationship between actual resting 
energy expenditure per kilogram of body mass [AREE/BM (Kg)], a significant 
difference was noted over the course of the diet (p < .001 ). Repeated measures of 
analysis of the variance identified a significant change between weeks 1 and 7. 
However, no significant change was noted between weeks 7 and 13, and between 
weeks 13 and 19. The relationship between weeks 19 and 25, however, did 
approach significance (p < .05). The significant values between actual resting 
energy expenditure and body mass over time are identified in Table 6. 
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TABLE 3. 
The predicted resting energy expenditure of subjects over the course of the diet. 
Variable 
Week Mean (kcal) so N 95%CI 
1 1715 147 17 1636-1793 
7 1622 133 17 1549-1692 
13 1547 127 17 1479-1615 
19 1514 118 17 1451-1577 
25 1523 121 16 1458-1587 
(p < .001) 
TABLE 4. 
The difference in means between actual and predicted resting energy 
expenditure of subjects over the course of the diet. 
Variable 
Week Mean(kcal) so N 95%CI 
1 58 146 17 -19-135 
7 118 115 17 56-179 
13 106 128 17 38-175 
19 85 126 17 17-152 
25 22 152 16 -59-103 
( p < .409) 
TABLE 5. 
The correlation between body mass (Kg) and resting energy expenditure (REE) 
over course of the diet 
Weight 7 
.0960 
17 
p=.357 
REE 7 
variable 
Weight 13 
.1686 
17 
p=.259 
REE13 
Weight 19 
.0752 
17 
p=.387 
REE19 
Weight 25 
.0989 
16 
p=.358 
REE25 
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FIG. 2. The relationship between actual resting energy expenditure (AREE) and 
predicted resting energy expenditure (PREE) over the course of the diet. 
TABLE 6. 
The relationship between actual resting energy expenditure (AREE) and body 
mass (Kg) over the course of the diet. 
Week 
1-7 
7-13 
13-19 
19-25 
AREE/BM 
p=.001 
Variable 
AREE/BM AREE/BM AREE/BM 
p=.095 
p=.609 
p=.095 
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Respiratory Quotient 
Repeated measures of analysis of variance examining the degree at which 
the variation of intakes affected changes in respiratory quotient (RQ) showed a 
statistically significant value (p < .001) for variation in RQ within subjects and 
between subjects over time. Table 7 identifies the change in RQ during the fasting, 
realimentation, and maintenance phases of the program. Figure 3 visualizes the 
change in RQ over the course of the diet. 
TABLE 7. 
The mean change in respiratory quotient over the course of the diet. 
Variable 
Week Mean SD N 95%CI 
1 .82 .07 17 .77-.86 
7 .74 .02 17 .73-.76 
13 .78 .05 17 .75-.80 
19 .78 .03 17 .76-.80 
25 82 08 16 78-86 
(p < .001) 
Anthropometries 
In examining the variability of measurements between circumference body fat (CBF) 
and infrared body fat (IBF), a significant correlation (p < .000) was noted between 
the percent body fat measured via circumference measurements and those done 
via infrared photospectrometry during the diet. The correlation between the two 
measurements became more significant as body mass loss progressed over the 
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course of the program. These are reflected in Tables 8 and 9. Figure 4 visualizes 
the positive correlation between circumference and infrared body fat measurements 
over time. Descriptive analysis was done on the fat body mass (FBM) and lean 
body mass (LBM) lost over the course of the diet. Table 10 identifies the mean 
differences between circumference and infrared body fat measurements over time. 
Pearson correlations reflected no significant change in the relationship between 
fat body mass and lean body mass over the course of the diet. This is identified in 
Table 11. Tables 12 and 13 identify the mean loss in fat and lean body mass during 
the course of the diet program. These losses are identified and compared to the 
0.84 
0.82 1-+--RQ I 
0.8 
0.78 
0.76 
0.74 
0.72 
Week1 Week? Week13 Week19 Week25 
FIG. 3. The change in respiratory quotient (RQ) over the course of the diet. 
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FIG. 4. The comparison of the circumference body fat(%) and infrared body fat(%) 
over the course of the diet. 
loss of total body mass in Figure 5. The relationship between body mass and 
percent body fat became more highly correlated over the course of the diet. This 
is identified in Table 14. No correlation was found between body fat mass and 
actual resting energy expenditure over time as noted in Table 15. When the 
relationship between lean body mass and resting energy expenditure was 
examined, a significant correlation (p = .001) was noted between the two 
parameters over time. Significance was noted between weeks 1 and 7. No 
significance was identified between weeks 7 and 13, and 13 and 19. The 
relationship approached significance between weeks 19 and 25, noted in Table 16. 
125 
100 
75 
50 
25 
0 
-25 
-50 
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LBM 
FIG. 5. The relationship between total body mass (TBM), lean body mass 
(LBM), and fat body mass (FBM) over the course of the diet. 
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TABLE 8. 
The t-test comparison between circumference and infrared body fat 
measurements over the course of the diet. 
Variable 
Two Tail 
N Mean(%) so Correlation Probability 
CBF1 17 39.4 5.0 .452 .11 
IBF1 36.9 6.4 
CBF7 17 35.1 5.0 .598 .02 
IBF7 31.9 6.5 
CBF13 17 30.9 5.0 .587 .77 
IBF13 31.2 2.9 
CBF19 17 29.8 5.2 .727 .55 
IBF19 30.4 3.4 
CBF25 16 30.5 4.7 .568 .40 
IBF25 31.4 3.2 
CBF - circumference body fat IBF - Infrared body fat 
TABLE 9. 
The correlation between infrared body fat (IBF) and circumference body fat 
(CBF) measurements over the course of the diet program. 
Variable 
IBF1 IBF7 IBF13 IBF19 IBF25 
N=17 N=17 N=17 N=17 N=16 
CBF1 .4523 
p=.034 
CBF7 .5981 
p=.006 
CBF13 .5872 
p=.007 
CBF19 .7271 
p=.OOO 
CBF25 .5680 
p=.011 
CBF - circumference body fat IBF - infrared body fat 
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TABLE 10. 
The difference between circumference body fat(%) and infrared body fat(%) 
means over the course of the diet. 
Variable 
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~ Meao(%) SD Mioimum Maxim11m 
CBF1 
IBF1 17 2.4 6.1 -14.1 9.8 
CBF7 
IBF7 17 3.2 5.3 -3.4 18.7 
CBF13 
IBF13 17 -.29 4.1 -6.6 7.4 
CBF19 
IBF19 17 -.52 3.6 -7.0 6.5 
CBF25 
IBF25 16 -.85 3.9 -9.6 6.5 
CBF - Circumference body fat IBF - Infra-red body fat 
TABLE 11 . 
The correlation between the change in fat body mass and lean body mass over 
the course of the diet. 
FBM1 
FBM7 
FBM13 
FBM19 
FBM25 
LBM1 
N=17 
0 
FBM - fat body mass 
LBM7 
N=17 
-.7281 
p=.OOO 
Variable 
LBM13 
N=17 
-.2672 
p=.148 
LBM - lean body mass 
LBM19 
N=17 
.1172 
p=.327 
LBM25 
N=16 
.0155 
p=.477 
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TABLE 12. 
The mean loss of fat body mass (FBM) over the course of the diet using infrared 
photospectrometry as a measurement. 
Variable 
N Mean(Kg} so Minimum Maximum 
FBM1 17 0.0 0.0 0.0 0.0 
FBM7 17 -8.2 3.0 -3.3 -13.9 
FBM13 17 -13.9 4.5 -7.7 -21.7 
FBM19 17 -15.7 4.8 -8.8 -24.0 
FBM25 16 -15.6 5.7 -6.7 -27.8 
TABLE 13. 
The mean Joss of lean body mass (LBM) over the course of the diet using 
infrared photospectrometry as a measurement. 
Variable 
N Mean( Kg) so Minimum Maximum 
LBM1 17 0.0 0.0 0.0 0.0 
LBM7 17 -3.3 3.0 1.9 -9.2 
LBM13 17 -3.7 2.9 1.0 -10.2 
LBM19 17 -5.1 3.2 1.8 -12.8 
LBM25 17 -4.8 3.1 -.4 -13.0 
TABLE 14. 
The correlation between body mass (Kg) and percent body fat (%BF) over the 
course of the diet. 
BM/%BF 7 
-.1364 
N=17 
p=.301 
BM/%BF 13 
.5635 
N=17 
p=.009 
BM/%BF 19 
.4750 
N=17 
p=.027 
BM/%BF 25 
.6558 
N=16 
p=.003 
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TABLE 15. 
The correlation between percent body fat (%BF) and resting energy expenditure 
(REE) over the course of the diet. 
BF%/REE7 
-.0615 
N=17 
p=.407 
TABLE 16. 
BF%/REE13 
.0490 
N=17 
p=.426 
BF%/REE19 
-.2211 
N=17 
p=.197 
BF%/REE25 
-.0522 
N=16 
p=.424 
The relationship between actual resting energy expenditure (AREE) and lean 
body mass (LBM(Kg)) over the course of the diet. 
Variable 
Week AREEILBM(Kg) AREEILBM(Kg) AREE/LBM(Kg) AREE/LBM(Kg) 
1-7 
7-13 
13-19 
19-25 
p=.001 
Biochemical 
p=.138 
p=.582 
p=.060 
The biochemical data by week using chi-square charts indicated no 
significant change in any biochemical parameter over the course of the diet 
regimen. However, secondary to the increased number of missing data, trusting the 
results is difficult. Cholesterol did show a significant change over the course of the 
diet (p ~ .020). Uric acid approached significance with (p ~ .076). Table 17 
identifies the mean biochemical profiles of subjects at baseline weeks. Figures 10 
through 26, as shown in Appendix D, illustrate the small variation in biochemical 
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parameters over the course of the diet. 
Lipid profiles, independent of body mass, taken before the start of the fast 
and after 6 weeks of maintenance showed no significance, but variations were 
identifiable. Tables 18 and 19 show the correlation between the difference of the 
two measurements with each parameter, and the mean differences. In Table 19, 
the DHL variable identified the difference in the ratio of high-density lipoproteins 
(HDL) to low-density lipoproteins (LDL). 
TABLE 17. 
The biochemical profile of subjects at baseline week, before the fast 
Variable 
Mean so Minimum Maximum 
Sodium (mmoi/L) 140 2.0 36 143 
Potassium (mmoi/L) 4.0 .3 3.4 4.7 
Chloride (mmoi/L) 107 2.7 103 111 
Glucose (mg/dL) 94 49 66 281 
BUN (mg/dL) 12 2.0 8 19 
Creatinine (mg/dL) 0.9 .2 .6 1.3 
Uric Acid (mg/dL) 5.6 1.1 3.5 7.7 
Total Protein(gm/dL) 7.0 .3 6.3 7.6 
Albumin (gm/dL) 4.2 .2 3.8 4.7 
Calcium (mg/dL) 9.2 .4 8.7 10.1 
Phosphorus (mg/dL) 3.4 .5 2.1 4.5 
Cholesterol (mg/dL) 202 30 143 245 
White Blood Cells 10"3JuL 7.5 1.4 5.2 10.0 
Red Blood Cells 10"6/uL 4.3 1.1 3.0 5.2 
Hemoglobin (gm/dL) 13.9 .9 12.0 15.8 
Hematocrit % 41.9 2.7 36.0 47.0 
Total Lymphocyte Count 2159 462 404 3171 
Count% 
TABLE 18. 
The correlation between the differences of measurements for each parameter 
examined in the lipid profile before the fast and after maintenance. 
DChol 
-.1407 
N=13 
p=.323 
DTG 
-.2910 
N=13 
p=.167 
DHDL 
-.1266 
N=13 
p=.340 
DVLDL 
.1037 
N=13 
p=.368 
DLDL 
.2659 
N=13 
p =.190 
DHL 
.0963 
N=10 
p=.396 
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D - difference, Chol -cholesterol, TG - triglycerides, HDL - high-density lipoproteins, VLDL - very-low-
density lipoproteins, LDL - low-density lipoproteins, DHL- difference in the ratio of high-density 
lipoproteins to low-density lipoproteins 
TABLE 19. 
The mean changes in lipid profile parameters over the course of the diet 
Variable 
Mean so Minimum Maximum 
Cholesterol 17 24 -23 51 
TG 45 48 -.5 155 
HDL -1.6 8.5 -16 13 
VLDL 6.7 13 -26 31 
LDL -20 67 -132 88 
DHL -.5 1.8 -5.8 .2 
TG - triglycerides, HDL - high-density lipoproteins, VLDL - very-low-density lipoproteins, LDL - low -
density lipoproteins, DHL - difference in ration between high-density lipoproteins and low-density 
I ipoproteins. 
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DISCUSSION 
Body Mass 
A significant loss in body mass of -20.442 .± 6.609 Kg was noted over the 
course of the diet program. These findings are consistent with investigators who 
associated the loss of body mass on a VLCD as superior to other nonsurgical 
treatment (5). The most significant loss in body mass occurred during the first 7 
weeks of the diet, or the fasting stage. This dramatic early loss of body mass could 
also have been attributed to diuresis. Subjects' loss of body mass appeared to slow 
after the fast and stabilized at week 25. Examining these subjects for a regain in 
body mass would be interesting and would determine the percentage of subjects 
who maintained a portion of their weight loss. 
Resting Energy Expenditure 
Both actual and predicted resting energy expenditure showed a significant 
decrease with body mass loss over the course of the diet. This is in agreement with 
the data obtained by Barrows and Snook (34), who identified a significant reduction 
in resting energy expenditure with weight loss using the Optifast-70 formula. 
Assuming the reduction in resting energy expenditure was caused by a loss in total 
body mass would be reasonable, as Coxon et al. (37) determined, the greater the 
weight loss the greater the decrease in resting energy expenditure. A significance 
was identified between actual resting energy expenditure per kilogram of body 
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mass between weeks 1 and 7, and weeks 19 and 25. The initial drop in actual 
resting energy expenditure during the initial phase of the fast relates to loss in body 
mass. However, the relationship between actual resting energy expenditure 
(AREE) and body mass [BM(Kg)] during stabilization may be conclusive with the 
data of Wadden et al. (4), who concluded a reduction in resting energy expenditure 
associated with the consumption of a VLCD may be limited to the actual period of 
the diet. Coxon et al. (37) concluded the change in resting energy expenditure was 
not associated with any specific component of body composition, as their data 
suggested no change in the ratio of resting energy expenditure (REE) to lean body 
mass (LBM), REE/LBM(Kg). However, this study did identify significance betvleen 
the loss in lean body mass and the change in resting energy expenditure. This 
does not relate to the findings of Franssila and Kallunki (41 ), who related the 
decrease in actual resting energy expenditure paralleled the loss in fat body mass, 
not lean body mass. Perhaps a larger sample size would have concluded 
otherwise. Exercise plays a major role in maintaining muscle mass during weight 
loss. This would have been an area of interest to be investigated as some subjects 
did not participate actively in exercise programs. It appeared patients' resting 
energy expenditures were on an upward trend from week 19 through week 25. 
Perhaps with further study the same conclusion could be drawn as that of other 
investigators (38, 39, 40) in which a reduction in resting energy expenditure was 
associated with a VLCD. However, the resting energy expenditure increased rapidly 
to 93-98% baselines when patients reached a stable reduced weight 
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Respiratory Quotient 
Patients' respiratory quotients paralleled each stage of the diet program. 
Results suggested patients initially were consuming a mixed balanced diet and as 
fasting began, values dropped to those values equal to patients being underfed, or 
those mobilizing fat for energy. These values returned to baseline when patients 
began the maintenance portion of the program. 
Anthropometries 
The variation in body composition associated with weight loss during a 
VLCD has prompted many researchers to suggest that anthropometric 
measurements could be inadequate for clinical assessment of body composition in 
obese patients. Circumference measurements may be more effective at estimating 
body fat as weight Joss progresses. This is in agreement with the findings of other 
researchers (34, 43). Near-infrared photospectrometry measurements showed a 
significant correlation with circumference measurements. The correlation between 
the two became more significant as weight Joss progressed. Therefore, near-
infrared photospectrometry is more accurate as weight Joss progresses and as 
patients reach desirable weight. The Joss in body mass progressed with losses in 
fat body mass (-15.6 Kg) being greater than those of lean body mass (-5.0 Kg). 
These findings could point to the fact that perhaps the change in actual resting 
energy expenditure was associated with total body mass lost, rather than an 
individual parameter. 
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Biochemical 
No significant changes were noted in complete blood count over the course 
of the diet program. Only cholesterol reflected a significant change (p ~ .020) in the 
SMA-12, with uric acid being close to significance (p ~ .076). These are in 
agreement with Kreitzman et al. (51) and Voliovitch et al. (52) who saw no change 
in hematocrit, hemoglobin, or any serum electrolytes (Na, K, Cl, Ca, P, Mg, Zn) . 
The one major medical concern with VLCD is the elevation in uric acid. This may 
predispose patients to gout. This could be a legitimate concern with the change in 
uric acid approaching significance in this study. No subjects were identified with 
gout during the diet. More conclusive data, however, may have yielded different 
results. The data suggest changes in cholesterol levels can be in response to a 
loss in total body mass. This is in agreement with Wadden et al. (4) . No 
significance was noted in the lipid profiles of patients before the fast and six weeks 
into maintenance. Variations in values appeared to fit those of other investigators 
(55, 56). Perhaps initial values fell during the diet and returned to normal at the 
end of the diet, consequently showing no change in the ratio of high- density 
lipoproteins (HDL) to low-density lipoproteins (LDL), (HDULDL). This would be in 
agreement with Parenti et al. {57). 
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CONCLUSION 
Obesity remains a chronic disease of major proportion in the U.S. and it 
continues to be a disease with no cure. Because obesity is a complex problem, a 
multidisciplinary approach to weight loss is still the best overall method in its 
management. VLCDs have received their share of criticism over the past decade. 
Complaints related to weight regain have been justified but not always presented 
in an unbiased manner. Other criticisms include the diet's adverse effects on 
resting energy expenditure and body composition but the criticisms have not been 
supported by the literature. Others criticisms require further study, such as the risk 
of gallstone formation and complications associated with gout. Despite the rave of 
criticism, VLCDs remain a highly effective option in the treatment of obesity, if 
accompanied by a multidisciplinary approach to patient care. They induce weight 
loss and control health complication in the obese. 
VLCD. 
Current research has lead to new conclusions concerning the clinical use of 
1. Studies have concluded no significant difference in weight loss between 
420 kcalld and 800 kcalld regimens. 
2. Success may be more directly related to portion and calorie controlled 
food then severe caloric restriction. 
3. Better effects may be noted by combining liquid meal supplements with 
solid food options. 
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From these conclusions, the new Optifast program "Promed" has been 
redesigned and changed from the old rigorous methods to more individualized 
regimens that cater to each patient's specific needs. It is anticipated that these 
changes will eliminate much of the controversy surrounding VLCDs and improve 
long-term maintenance of weight loss. The primary goal of the new concepts is to 
improve long-term maintenance of weight loss and the medical complications. An 
increasing awareness of the chronic, multifactorial nature of obesity will lead to the 
development of safe and effective long-term treatment programs (3) . 
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All data except the body circumference measurements and NIR 
photospectrometry will be collected by the Optifast program at McKay-Dee Hospital. 
Circumference and photospectrometry (NIR) readings will be collected by the 
investigator, with supervision by the Optifast program director. The Optifast 
program is already conducting resting metabolic readings via indirect calorimetry 
through respiratory therapy, the additional Beckman readings will also be collected 
by respiratory therapy. Research subjects will be at minimal risk besides those 
outlined by the Optifast program. Subjects will not be identified by name but by 
number to safeguard confidentiality. 
Funding is needed for the three additional Beckman readings only; and will 
be provided by Utah State University Department of Nutrition & Food Sciences. 
Therefore, will be no extra cost to the subjects. 
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Appendix B 
Participant Letter 
Dear Participant: 
A study is being conducted by Charlene Perkins a graduate student in 
Nutrition at Utah State University, evaluating the Optifast 70 diet and it's effects on 
resting metabolic rate, body composition, blood electrolytes and cholesterol. All 
tests involved in the study are included in the Optifast Program except the body 
composition measurements. Your participation would be appreciated. 
Factors to be considered in the study: 
1. Resting metabolic rate (RMR) will be measured with a Beckman 
Metabolic cart, which determines RMR by measuring oxygen consumption through 
a mask while resting in a quiet environment. This procedure will be done during 
weeks one (1), seven (7), thirteen (13), nineteen (19), and twenty-five (25). It will 
take approximately 45 minutes and an appointment should be made no less than 
7 days in advance. Measurements must be taken during the same time of day for 
each consecutive week. This information will help to determine the effects calorie 
restriction has on resting metabolic rate. 
2. On the same weeks as above, body composition will be evaluated by 
taking circumference measurements of the arm, waist buttocks, thigh and calf. 
Body composition will also be examined using a Futrex-500 Fitness Computer, 
which assesses body composition using light beams. The measurement will be 
taken on the prominent arm midway between the shoulder and elbow, and will only 
takes a couple of minutes. These measurements will help to evaluate the effects 
of calorie restriction on body composition particularly fat and muscle. 
3. On the same weeks as above your blood chemistry results will be 
evaluated concerning electrolytes and cholesterol. These results will give a basic 
overview of how the Optifast diet effects your blood chemistry. 
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Appendix C 
Consent Form 
It has been explained to me that Miss Perkins will conduct the body 
composition measurements and the Optifast Program will conduct the remaining 
tests, including the RMR, blood electrolytes and blood minerals. 
I understand the information obtained in this study will be held in strict 
confidence. If this study is published I have been assured there will be no 
information disclosed which identifies me as a participant. 
I understand there is no perceived risk to me participating in this study. Any 
questions that I have regarding the study have been answered to my satisfaction. 
I understand I am free to withdraw from the study, at any time, for any 
reasons of my choosing, without my standard of care being affected . 
I understand that there is no additional cost to me for participating in this 
study. 
Any questions may be answered by calling Miss Perkins at 801n50-2139 or 
801 /7 53-4595. 
Date 
Signature of Investigator 
Signature of Optifast 
Program Director 
Signature of Participant 
Signature of Principal 
Investigator 
146 
145 
144 
143 
142 
141 
140 
139 
138 
137 
136 
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Appendix D 
Changes in Biochemical Data over the Course of the Diet 
!-+-Sodium (mmoi/L) I 
135+-----~------~-----r----~r-----,-----~------. 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 6. The change in serum sodium over the course of the diet. 
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5 
4.5 I-+-Potassium (mmoi/L) I 
4 
3.5+-----~------~----~------~----~------~-----. 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 7. The change in serum potassium over the course of the diet. 
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6.5 
6 I-+-Uric Acid (mg/dl) I 
5.5 
5 
4 .5 
4+-----~------~----~------~----~------~----~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 8. The change in serum uric acid over the course of the diet. 
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109 
108 
1-+-Chloride (mmoi/L) I 
107 
106 
105 
104~----~----~~----~----~----~~----~----~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 9. The change in serum chloride over the course of the diet. 
200 
190 
180 
170 
160 
150 
1-+-Cholesterol (mg/dl) I 
68 
140+-----~----~------~----~----~------~----~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 10. The change in serum cholesterol over the course of the diet. 
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100 
95 
90 I-+- Glucose (mg/dL) I 
85 
80 
75 
70 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 11. The change in serum glucose over the course of the diet. 
20 
18 
16 
14 
12 
10 
8 
70 
I~ BUN (mg/dl) I 
6+-----~------r-----~-----,------~----------~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 12. The change in serum blood urea nitrogen (BUN) over the course of 
the diet. 
1.5 
1.3 
1.1 
0.9 
0.7 
71 
I-+-Creatinine (mg/dl) I 
0.5 -+-----""T----r-------.----r-------.-----r------. 
Week 1 Week 5 Week 9 Week 13 Week !7 Week 21 Week 25 
FIG. 13. The change in serum creatinine over the course of the diet. 
8 
7.8 
7.6 
7.4 
7.2 
7 
6.8 
6.6 
6.4 
-+-Total Protein 
(gm/dl) 
6.2 +------.----.r-----.,.------.----.r-----.,.-----, 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 14. The change in serum total protein over the course of the diet. 
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4.9 
4.7 
4.5 
4.3 
4.1 
3.9 
3.7 
73 
I-.--Albumin (gm/dl) I 
3.5+-----~------~----~------~----~----~----~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 15. The change in serum albumin over the course of the diet. 
74 
10 
!-+-Calcium (mg/dl) I 
9.8 
9.6 
9.4 
9.2 
9 
8.8 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 16. The change in serum calcium over the course of the diet. 
4.5 
4 
3.5 
--+- Phosphorus 
(mg/dL) 
75 
3+-----~------~------~----~------~----~------~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 17. The change in serum phosphorus over the course of the diet. 
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8 
-+-White Blood Cells (WBC) 
(10"3/uL) 
7.5 
7 
6.5 
6+------.------.-----.------.------.-----.------. 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 18. The change in serum white blood cells (WBC) over the course of the 
diet. 
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4 .7 
4.6 
4.5 
4.4 
4.3 
__.__ Red Blood Cells 
(RBC) (1 QA3ful) 
77 
4.2 +----,-----r-------.----..-----r----.-------, 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 19. The change in serum red blood cells (RBC) over the course of the 
diet. 
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13.9 
13.8 
13.7 
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I-+-Hemoglobin (gm/dL) I 
13.3+-----~----~------r-----~-----r----~----~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 20. The change in serum hemoglobin over the course of the diet. 
42.5 
42 
41.5 
41 
40.5 
I-+-Hematocrit (%) I 
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40+-----~------~----~----~------~----~----~ 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 21 . The change in serum hematocrit over the course of the diet. 
2500 
2400 
2300 
2200 
2100 
2000 
-+--Total Lymphocyte 
Count (TLC %) 
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1900+-----~----~----~----~------~----.-----. 
Week 1 Week 5 Week 9 Week 13 Week 17 Week 21 Week 25 
FIG. 22. The change in serum total lymphocyte count over the course of the 
diet. 
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Appendix E 
SUBJECT DATA 
Age Ht Weight CBF IBF FBM LBM TBM AREE PREE REE/Kg RQ 
A 54 160 109.698 45.4 36.3 39 70 49.6 1867 1724 17.4 .89 
95.227 37.7 36.6 35 60 49.3 1574 1625 16.0 .75 
85.227 32.6 32.4 27 57 51 .8 1383 1512 16.0 .75 
80.545 33.9 31.1 26 55 52.2 1472 1472 18.0 .80 
77.681 28.2 30.8 24 53 52.8 1585 1446 21.0 .82 
B 33 167 90.454 32.3 31 .1 28 62 52.7 1607 1645 18.4 .87 
76.409 28.4 28.8 22 54 54.2 1386 1563 17.0 .74 
67.272 21.4 28.0 19 48 57.4 1269 1463 18.6 .72 
65.500 21 .2 25.6 16 48 56.4 1380 1428 21.0 .81 
71 .681 24.7 27.9 20 51 54.9 1420 1467 21 .0 .81 
C60 164 99.227 37.4 35.6 35 64 49.7 1639 1614 16.7 .73 
86.818 37.2 35.5 30 56 49.9 1518 1514 17.0 .74 
79.636 27.5 32.9 26 56 49.9 1240 1436 15.6 .73 
77.227 26.8 31 .8 25 53 52.3 1492 1401 20.0 .75 
77.272 26.8 31 .9 25 53 52.2 1381 1414 18.0 .74 
027 173 114.181 39.9 34.0 37 75 50.9 1822 1944 15.9 .73 
99.363 37.6 31 .9 31 68 52.5 1727 1818 17.3 .70 
88.772 34.2 29.4 26 62 53.6 1653 1700 18.6 .77 
82.727 32.6 28.6 23 59 54.4 1532 1631 19.0 .73 
80.954 31 .4 27.0 21 60 55.9 1584 1613 20.0 .83 
E48 165 75.909 32.7 30.8 23 53 52.9 1305 1462 17.2 .91 
68.272 28.2 29.2 20 48 54.2 1162 1388 17.0 .80 
65.000 26.2 28.5 19 46 54.2 1081 1349 17.0 .82 
64.500 24.8 27.3 17 46 55.3 1011 1332 16.0 .81 
62.272 25.8 35.5 22 40 49.9 1176 1323 19.0 .81 
F 47 174 115.360 38.8 38.0 44 71 47.6 1854 1850 16.0 .75 
1 02.727 40.3 30.6 31 71 53.2 1660 1752 15.9 .72 
97.090 34.1 28.9 28 69 54.2 1638 1678 17.0 .71 
94.091 31.0 29.3 27 66 53.9 1683 1644 18.0 .73 
95.540 33.5 29.6 28 67 53.7 1941 1648 21 .0 .93 
G 41 160 112.682 48.0 38.2 44 70 48.0 1864 1833 16.6 .84 
103.181 45.9 37.4 38 65 48.6 1554 1750 15.0 .76 
98.636 43.5 36.1 35 63 49.6 1858 1707 19.0 .82 
96.818 42.3 35.8 35 62 49.7 1488 1690 15.0 .81 
96.818 42.2 35.8 35 62 49.7 1510 1690 16.0 .80 
H 59 160 76.909 33.0 31.8 24 52 52.3 1331 1401 17.5 .84 
67.727 29.5 31.5 21 46 52.7 1280 1461 16.7 .87 
62.272 27.5 30.1 19 43 53.4 1145 1311 18.3 .94 
62.272 26.6 30.0 19 45 53.6 1340 1271 22.0 .91 
NO DATA FOR WEEK25 
82 
Age Ht Weight CBF IBF FBM LBM TBM AREE PREE REE/Kg RQ 
164 160 83.181 37.1 51 .2 42 40 39.7 1552 1447 20.0 .93 
75.000 29.8 33.2 25 50 51 .5 1113 1378 15.0 .72 
70.090 27.3 32.3 22 47 52.0 1268 1326 18.0 .68 
72.181 25.8 32.8 23 48 51.6 1360 1326 19.0 .74 
72.500 29.2 32.4 23 49 51.9 1376 1348 18.0 .67 
J 35 163 99.864 45.0 53.1 53 48 38.6 1475 1748 15.0 .75 
87.863 35.1 33.9 30 58 51 .0 1653 1647 19.0 .71 
77.954 29.6 30.1 23 54 53.3 1540 1540 21 .0 .79 
72.909 29.6 29.0 20 52 54.3 1573 1488 22.0 .73 
74.545 28.5 30.1 22 52 53.6 1390 1509 20.0 .82 
K45 163 96.364 42.0 35.7 34 63 50.1 1650 1667 17.0 .76 
83.954 36.5 32.4 27 56 51.8 1256 1558 15.0 .76 
76.318 32.4 31 .3 24 52 52.6 1161 1476 15.0 .83 
75.454 29.5 30.6 23 52 53.3 1236 1463 17.0 .82 
77.273 30.9 31 .6 24 53 52.4 1371 1458 18.0 .98 
L 57 155 130.454 45.2 42.6 55 75 45.4 2149 1936 16.0 .74 
116.363 41.9 41.5 48 68 46.0 1658 1840 14.0 .73 
113.409 37.3 39.1 44 69 47.7 1478 1749 14.0 .76 
1 08.409 38.5 39.3 42 65 47.3 1616 1710 15.0 .79 
108.636 38.6 39.0 42 66 47.4 1850 1749 17.0 .87 
M44 170 95.772 38.6 32.5 31 69 51 .9 1433 1655 15.0 .76 
85.181 35.5 30.6 26 59 53.1 1505 1590 17.0 .75 
80.318 33.2 29.0 23 56 54.0 1306 1529 16.0 .77 
79.545 32.8 28.6 23 56 54.2 1365 1521 18.0 .86 
80.000 32.6 29.6 23 56 53.8 1222 1525 16.0 .73 
N 28 172 95.591 36.8 32.5 30 65 52.1 1703 1717 18.0 .95 
82.909 32.5 29.9 25 58 53.5 1534 1619 18.0 .76 
76.454 27.5 28.0 21 55 54.8 1530 1532 21 .0 .80 
68.636 23.8 25.3 17 51 56.4 1513 1472 22.0 .79 
69.090 24.7 26.0 18 51 56.2 1622 1476 23.0 .84 
042 155 88.409 33.5 35.4 31 57 49.9 1446 1582 17.0 .91 
78.545 29.6 32.9 25 53 51 .6 1334 1525 17.0 .78 
75.454 27.8 32.7 25 50 51 .7 1512 1482 21.0 .82 
72.500 28.2 31 .6 22 48 52.8 1209 1464 17.0 .77 
76.545 29.9 33.0 25 51 51 .5 1376 1473 20.0 .82 
p 28 165 102.090 39.4 33.6 34 67 51.1 1540 1803 16.0 .82 
91 .318 34.4 31 .4 29 62 52.4 1782 1699 20.0 .76 
84.727 30.2 29.8 24 58 53.5 1484 1612 18.0 .77 
82.272 30.2 29.8 24 58 53.5 1484 1612 18.0 .77 
84.818 30.6 30.9 25 59 53.1 1488 1634 18.0 .96 
Q 32 164 1 06.409 45.6 36.9 30 76 00.0 1608 1815 15.0 .80 
94.636 38.2 35.0 33 61 50.2 1543 1715 16.0 .80 
85.727 31.4 33.0 28 57 51.5 1572 1632 18.0 .87 
80.227 30.5 30.9 25 55 53 1458 1580 19.0 .78 
82.909 32.1 31.5 25 57 52.6 1773 1597 21 .0 .75 
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Na K Cl glue BUN Creat UA TP alb Ca p Chol 
A1 142 3.9 104 78 12 .9 5.7 7.0 4.3 10 3.6 234 
AS 137 4.2 103 90 16 1.0 5.7 6.8 4.4 9.6 3.5 166 
A9 137 3.9 104 85 13 .9 4.6 6.5 4.2 9.5 3.8 143 
A13 140 4.2 105 76 16 .9 55 6.5 4.1 9.5 4.0 166 
A17 no data 
A21 140 3.9 107 76 12 .9 5.2 6.5 4.3 9.2 4.1 195 
A25 141 4.1 107 78 11 1.0 5.3 6.3 4.1 8.9 4.1 187 
81 140 4.1 105 66 10 .7 5.2 7.6 4.4 9.5 4.5 175 
85 139 4.1 105 72 14 .9 7.1 7.4 4.4 9.8 3.9 112 
89 139 3.9 105 68 13 .8 5.6 7.4 4.3 9.6 4.0 107 
813 140 4.1 107 61 13 .7 5.5 7.6 4.5 9.8 4.3 109 
817 138 4.2 106 71 15 .8 4.3 7.3 4.4 9.7 4.5 148 
821 139 4.3 105 69 12 .9 4.7 7.2 4.5 9.4 4.4 144 
825 141 4.2 116 85 12 .8 5.7 7.1 4.1 8.8 4.2 164 
C1 141 4.0 106 75 19 .9 6.1 7.1 4.2 9.2 4.2 231 
C5 139 3.9 106 91 20 1.0 5.8 6.8 4.3 9.6 4.3 229 
C9 140 4.0 107 90 20 .9 5.2 6.5 4.1 9.6 4.3 171 
C13 142 4.3 109 85 26 .9 5.6 7.1 4.4 9.8 4.6 195 
C17 142 4.3 110 95 21 .9 5.8 6.7 4.1 9.3 4.3 218 
C21 139 4.3 106 99 18 1.0 5.9 6.7 4.0 9.2 4.3 224 
C25 141 4.5 108 85 17 .8 5.8 6.7 4.1 9.1 4.1 235 
01 143 4.2 110 77 10 1.0 7.7 7.6 4.7 9.7 3.6 245 
05 139 3.9 107 64 13 1.0 9.6 7.0 4.6 9.6 2.9 158 
09 140 4.0 109 72 12 .9 7.0 7.2 4.7 9.6 3.1 161 
013 138 4.1 109 90 18 1.0 6.7 6.9 4.6 9.7 3.1 178 
017 139 4.1 110 87 9 .9 6.0 6.7 4.5 9.8 3.1 213 
021 139 4.0 107 116 9 .9 6.8 7.0 4.7 9.7 3.4 209 
025 139 4.4 108 91 11 1.0 5.6 6.7 4.5 9.5 2.8 188 
E1 137 4.2 104 68 13 1.2 7.1 6.5 4.0 9.6 2.8 178 
E5 139 4.2 107 78 22 1.1 5.4 6.8 4.3 10.3 3.3 129 
E9 136 4.5 106 70 18 1.2 5.3 6.7 4.4 10.3 2.7 137 
E13 137 4.6 108 74 20 1.1 5.3 6.9 4.4 10.4 3.2 137 
E17 137 4.7 107 77 20 1.2 6.3 6.7 4.4 10.3 2.7 117 
E21 139 4.6 108 83 21 1.3 6.0 7.0 4.5 10.6 3.4 123 
E25 140 4.3 105 74 13 1.4 6.1 7.3 3.8 10.1 2.0 142 
F1 138 3.7 103 97 12 .6 4.7 6.9 4.1 8.9 3.0 200 
F5 138 4.6 105 78 14 .7 4.0 7.4 4.4 9.9 3.9 177 
F9 141 4.6 106 82 14 .8 3.4 7.2 4.3 10.0 4.2 179 
F13 138 4.6 107 85 14 .7 3.7 7.1 4.2 9.7 3.9 186 
F17 139 4.4 106 82 20 .3 4.7 7.4 4.4 9.7 4.3 197 
F21 141 4.4 105 87 20 .8 4.1 7.7 4.6 10.0 4.6 187 
F25 141 4.4 103 87 16 1.0 4.0 7.7 3.4 9.1 3.5 185 
G1 140 4.0 107 96 13 .8 4.3 7.2 4.6 9.1 2.8 182 
G5 139 4.3 106 75 14 .8 4.6 6.8 4.5 9.8 3.6 149 
G9 143 4.4 110 78 11 .8 3.5 7.1 4.7 9.7 3.3 169 
G13 140 4.4 108 75 9 .7 3.9 6.9 4.6 9.6 3.2 170 
G17 141 4.4 111 73 10 .8 3.9 7.0 4.7 9.8 3.2 177 
84 
Na K Cl glue BUN Creat UA TP alb Ca p Chol 
G21 no data 
G25 138 4.2 101 68 11 1.0 3.5 7.4 4.2 8.9 3.0 186 
H1 142 4.3 107 . 92 17 1.2 1.0 7.3 4.4 9.1 3.2 324 
H5 139 4.3 103 83 24 1.2 5.7 6.9 4.2 9.6 3.4 185 
H9 142 4.1 107 92 30 1.1 4.9 6.8 4.2 9.6 4.5 194 
H13 140 4.4 108 89 24 .9 5.0 6.4 3.9 8.9 4.4 211 
H17 138 4.5 106 90 29 .9 5.6 6.2 3.7 8.8 3.7 221 
H21 137 4.4 105 87 24 1.0 5.2 6.7 4.0 9.3 4.0 247 
H25 no data 
11 143 3.4 111 75 15 1.1 4.7 6.6 4.1 8.7 2.1 223 
15 141 4.0 107 80 20 1.2 5.5 7.4 4.6 9.8 2.7 191 
19 140 4.7 107 82 22 1.2 4.6 6.9 4.4 9.8 2.6 194 
113 140 4.4 108 79 20 1.2 4.3 6.7 4.2 9.4 2.3 220 
117 140 4.2 105 74 16 1.2 5.2 6.8 4.3 9.7 2.1 242 
121 141 4.1 102 61 23 1.4 5.1 7.8 3.7 9.6 2.6 252 
125 142 3.9 106 95 19 1.3 4.5 7.0 3.3 8.2 2.3 211 
J1 138 3.9 106 84 14 .6 4.3 7.2 4.3 8.8 3.5 215 
J5 143 3.8 109 70 11 .9 6.0 6.6 4.3 9.3 3.9 155 
J9 140 3.7 108 74 13 .8 5.1 6.6 4.2 9.4 3.7 151 
J13 139 4.0 106 78 14 .6 5.1 6.6 4.2 9.5 3.8 155 
J17 137 3.7 109 78 11 .8 4.8 6.3 4.2 9.6 3.2 170 
J21 141 3.3 103 74 9 1.0 4.8 7.1 3.7 9.5 3.3 187 
J25 141 3.9 104 74 11 .9 4.2 7.0 3.7 9.0 3.5 189 
K1 143 3.8 109 107 12 .9 6.5 7.3 4.6 10.1 4.0 225 
K5 139 3.8 103 80 16 1.0 7.1 7.8 4.8 10.3 4.1 157 
K9 139 4.1 104 83 20 .8 5.2 7.3 4.7 10.5 4.6 162 
K13 143 3.9 108 79 12 .8 4.7 6.7 4.4 10.2 4.2 169 
K17 143 4.1 102 80 14 1.0 5.2 7.6 4.1 10.4 4.2 229 
K21 no data 
K25 146 4.6 106 91 12 1.0 5.4 7.2 3.6 9.5 3.4 203 
L1 141 4.3 105 281 9 .7 6.3 6.9 4.0 9.1 3.7 225 
L5 140 4.2 104 99 13 .8 9.1 7.3 4.4 9.9 4.0 190 
L9 140 3.9 104 85 12 .8 8.7 7.2 4.4 9.4 3.7 220 
L13 142 4.0 108 87 21 .9 10.0 7.0 4.2 9.8 4.3 204 
L17 143 4.3 101 74 19 1.0 8.1 7.8 3.8 9.0 4.1 204 
L21 no data 
L25 143 4.0 103 118 15 .9 6.4 7.5 3.4 9.1 3.8 229 
M1 136 4.5 104 89 13 1.3 4.8 7.0 3.9 8.7 3.2 191 
M5 139 4.2 105 75 13 1.1 5.1 7.7 4.7 9.9 3.5 156 
M9 139 4.2 106 70 13 1.1 5.0 7.1 4.5 9.7 3.4 170 
M13 no data 
M17 139 3.9 103 67 17 1.0 4.9 7.1 4.4 9.4 3.3 190 
M21 139 4.4 100 69 19 1.2 4.8 8.4 4.3 9.9 3.4 194 
M25 138 4.1 103 84 14 1.1 4.1 7.2 3.7 9.0 3.4 189 
N1 141 4.6 110 81 10 .7 3.5 6.9 4.4 9.2 3.1 163 
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Na K Cl glue BUN Creat UA TP alb Ca p Chol 
NS 137 4.2 107 81 12 .9 4.5 6.6 4.3 9.5 3.5 108 
N9 138 4.2 106 69 9 .8 4.1 6.5 4.3 9.5 3.9 109 
N13 139 4.0 107 73 9 .8 3.5 6.5 4.5 9.8 3.9 123 
N17 141 4.1 102 65 11 .8 2.5 7.4 4.3 9.7 3.7 139 
N21 no data 
N25 139 3.9 102 81 9 .9 3.4 7.2 3.9 9.1 4.0 148 
01 140 3.9 111 78 8 .9 4.7 6.9 4.2 9.1 3.6 242 
05 135 4.5 106 88 19 1.0 5.3 7.3 4.5 9.6 3.2 155 
09 138 4.2 107 93 19 .9 4.1 7.0 4.4 9.5 4.5 202 
013 138 4.2 105 84 15 1.0 6.3 7.3 4.8 9.9 3.9 195 
017 139 4.0 101 88 12 1.0 4.0 8.2 4.2 9.6 4.0 220 
021 no data 
025 139 4.6 108 68 13 1.1 4.4 7.5 3.8 8.6 3.7 206 
P1 142 3.8 110 88 8 .9 6.5 7.1 4.4 9.2 3.4 143 
PS 140 4.6 105 79 16 .9 7.6 7.2 4.5 10.0 3.7 102 
P9 142 4.5 107 78 17 .8 5.1 6.9 4.4 9.7 4.0 126 
P13 141 4.4 105 92 13 1.0 6.7 7.5 4.6 10.1 4.6 131 
P17 144 3.8 102 85 13 1.1 5.3 7.6 3.9 8.9 4.3 113 
P21 143 3.8 108 78 14 1.1 4.3 7.6 3.8 8.8 4.1 113 
P25 143 4.5 106 84 12 .9 4.4 7.2 3.7 8.7 4.0 110 
01 141 4.7 109 93 12 .9 5.2 6.3 3.8 8.9 3.7 175 
as 136 4.0 104 85 11 .9 5.5 6.4 4.0 9.4 3.6 156 
09 138 3.7 106 79 9 .8 4.8 6.4 4.1 9.2 3.6 149 
013 138 4.1 108 85 8 .9 5.0 6.0 3.8 8.8 3.9 140 
017 139 4.0 100 81 18 1.0 3.7 7.0 3.5 9.0 3.5 169 
021 139.3.9 102 89 12 1.0 4.2 7.0 3.5 8.9 4.2 174 
025 no data 
WBC RBC Hgb Hct TLC 
A1 8.6 4.6 13.9 42 1522 
AS 6.2 4.6 13.9 42 1457 
A9 5.3 4.2 12.9 40 1071 
A13 4.8 4.4 13.3 41 1344 
A17 5.9 4.2 13.1 59 1381 
A21 5.9 4.2 13.1 40 1381 
A25 5.1 4.4 14.1 42 995 
81 10.5 4.8 14.7 43 3171 
85 8.0 4.5 13.7 41 2704 
89 7.6 4.5 13.4 40 2592 
813 7.8 4.6 13.8 42 2449 
817 9.0 4.5 13.3 41 3100 
821 8.8 4.6 13.8 42 2693 
825 11 4.2 12.8 38 3025 
C1 8.0 4.7 13.8 41 2688 
cs 6.5 4.5 13.2 40 2305 
C9 6.2 4.4 12.6 39 2151 
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WBC RBC Hgb Hct TLC 
C13 6.3 4.6 13.2 41 2388 
C17 8.1 4.5 13.2 40 2680 
C21 8.2 4.4 12.5 38 2640 
C25 6.9 4.5 13.4 39 1925 
01 8.3 5.1 14.4 43 2473 
05 6.4 5.1 13.9 42 2086 
09 6.6 5.2 14.1 44 1940 
013 8.9 5.2 14.3 44 2198 
017 7.4 4.9 13.7 43 2494 
021 7.3 4.9 14.3 43 2175 
025 6.8 4.8 14.5 43 1584 
E1 9.0 4.3 13.3 41 1782 
E5 7.6 4.3 13.6 41 2265 
E9 8.6 4.3 13.3 41 2167 
E13 8.9 4.7 14.1 44 2456 
E17 6.9 4.3 13.4 41 2063 
E21 no data 
E25 7.9 4.9 15.4 46 2054 
F1 7.3 4.3 12.7 39 2679 
F5 5.9 4.2 12.5 38 2572 
F9 6.0 4.2 12.1 38 2628 
F13 7.0 4.1 11.8 37 2541 
F17 5.1 4.1 12.1 37 2621 
F21 6.3 4.4 13.2 40 2848 
F25 4.8 4.1 12.3 36 2140 
G1 7.4 4.9 14.7 44 2042 
G5 6.3 4.8 14.2 43 1852 
G9 6.1 4.9 14.4 44 1537 
G13 7.7 4.9 14.4 44 2202 
G17 no data 
G21 no data 
G25 5.8 4.9 14.4 43 1833 
H1 6.9 4.8 14.5 43 1987 
H5 6.1 4.6 13.7 42 2220 
H9 5.7 4.5 13.4 41 1870 
H13 6.8 4.3 12.8 39 2264 
H17 7.0 4.4 13.1 40 2142 
H21 7.7 4.9 14.3 43 2349 
H25 no data 
11 6.0 4.4 13.0 39 2268 
15 5.7 4.8 14.2 43 2234 
19 5.2 4.6 13.6 42 2210 
113 5.6 4.5 13.5 41 2442 
117 6.6 4.5 13.8 42 2653 
121 7.7 4.6 14.4 43 2333 
125 6.0 4.1 12.7 38 2016 
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WBC RBC Hgb Hct TLC 
C13 6.3 4.6 13.2 41 2388 
C17 8.1 4.5 13.2 40 2680 
C21 8.2 4.4 12.5 38 2640 
C25 6.9 4.5 13.4 39 1925 
01 8.3 5.1 14.4 43 2473 
05 6.4 5.1 13.9 42 2086 
09 6.6 5.2 14.1 44 1940 
013 8.9 5.2 14.3 44 2198 
017 7.4 4.9 13.7 43 2494 
021 7.3 4.9 14.3 43 2175 
025 6.8 4.8 14.5 43 1584 
E1 9.0 4.3 13.3 41 1782 
E5 7.6 4.3 13.6 41 2265 
E9 8.6 4.3 13.3 41 2167 
E13 8.9 4.7 14.1 44 2456 
E17 6.9 4.3 13.4 41 2063 
E21 no data 
E25 7.9 4.9 15.4 46 2054 
F1 7.3 4.3 12.7 39 2679 
F5 5.9 4.2 12.5 38 2572 
F9 6.0 4.2 12.1 38 2628 
F13 7.0 4.1 11 .8 37 2541 
F17 5.1 4.1 12.1 37 2621 
F21 6.3 4.4 13.2 40 2848 
F25 4.8 4.1 12.3 36 2140 
G1 7.4 4.9 14.7 44 2042 
G5 6.3 4.8 14.2 43 1852 
G9 6.1 4.9 14.4 44 1537 
G13 7.7 4.9 14.4 44 2202 
G17 no data 
G21 no data 
G25 5.8 4.9 14.4 43 1833 
H1 6.9 4.8 14.5 43 1987 
H5 6.1 4.6 13.7 42 2220 
H9 5.7 4.5 13.4 41 1870 
H13 6.8 4.3 12.8 39 2264 
H17 7.0 4.4 13.1 40 2142 
H21 7.7 4.9 14.3 43 2349 
H25 no data 
11 6.0 4.4 13.0 39 2268 
15 5.7 4.8 14.2 43 2234 
19 5.2 4.6 13.6 42 2210 
113 5.6 4.5 13.5 41 2442 
117 6.6 4.5 13.8 42 2653 
121 7.7 4.6 14.4 43 2333 
125 6.0 4.1 12.7 38 2016 
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W8C R8C Hgb Hct TLC 
P17 8.4 5.1 15.4 46 2814 
P21 8.8 5.1 15.4 46 2939 
P25 8.0 4.9 14.5 43 2216 
01 6.5 4.4 13.0 40 1970 
as 4.7 4.5 13.2 41 1673 
09 5.8 4.4 13.2 39 1380 
013 4.5 4.7 13.5 41 1735 
017 6.2 4.4 13.3 40 1953 
021 7.4 4.5 13.4 40 2220 
025 6.2 4.2 12.3 38 1476 
CHOL TG HDL VLDL LDL 
A1 220 138 84 28 108 
A25 196 117 82 23 91 
81 147 60 54 12 81 
825 170 65 46 13 111 
C1 209 148 65 30 114 
C25 245 127 73 25 147 
01 213 116 68 23 122 
025 212 91 58 18 36 
E1 164 219 49 44 71 
E25 131 64 36 13 88 
F1 183 85 70 17 96 
F25 182 69 75 14 93 
G1 170 121 49 24 97 
G25 181 122 46 24 117 
H1 310 245 63 49 212 
H25 I I I I I 
11 244 175 63 35 125 
125 208 122 63 24 121 
J1 232 71 71 14 147 
J25 189 74 68 15 106 
K1 240 235 58 47 135 
K25 206 98 69 20 117 
L1 225 199 34 40 151 
L25 218 159 42 32 144 
M1 191 158 40 I I 
M25 195 129 48 26 121 
N1 176 92 46 18 99 
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CHOL TG HDL VLDL LDL 
N25 163 44 62 9 92 
01 249 143 36 29 I 
025 198 97 47 19 132 
P1 145 69 36 14 93 
P25 104 39 31 8 5 
01 181 147 32 29 I 
025 25 100 34 20 130 
Appendix F 
Abbreviations 
Age- years 
Height- centimeters 
Body Mass - kilograms 
CBF/Circumference Body Fat-% 
IBF/Infra-red Body Fat-% 
FBM/Fat Body Mass - kilograms 
LBM/Lean Body Mass- kilograms 
TBW/Total Body Water-% 
AREE/Actual Resting Energy Expenditure - kcal 
PREE/Predicted Resting Energy Expenditure - kcal 
REE/Resting Energy Expenditure - kcal 
RQ/Respiratory Quotient 
VLCD - very-low-calorie-diet 
CBC - complete blood count 
SMA-12 - serum chemistry panel 
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Appendix G 
Normal Laboratory Values 
Sodium - Na (mmol) 
Potassium - K (mmoi/L) 
Cholride - Cl (mmoi/L) 
Glucose (mg/dL) 
BUN (mg/dL) 
Creatinine (mg/dL) 
Total Protein (gm/dL) 
Albumin (gm/dL) 
Calcium (mg/dL) 
Phosphorus (mg/dL) 
Cholesterol (mg/dL) 
Uric Acid (mg/dL) 
White Blood Cells (1 0"3/uL) 
Red Blood Cells (10"3/uL) 
Hemoglobin (g/dL) 
Hematocrit (%) 
Total Lymphocyte Count(%) 
135-146 
3.5-5.1 
100-112 
70-115 
6-20 
.5-1.6 
6.2-8.0 
3.4-5.0 
8.5-10.6 
2.4-4.5 
0-200 
2.4-7.5 
5.0-10.0 
4.5-6.2 
14-18 
43-56 
20-40 
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